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After 1 Year
Paulette Wehner, MD, FACC, FCCP, FACP, FAHA; William Nitardy, MD
W hen chronic kidney disease (CKD) is part of the clinicalhistory for a patient with acute myocardial infarction,
the interventional cardiologist experiences an increased
anxiety level. An acute myocardial infarction with renal
disease requires more attention to dye load and fluid status,1
and general opinion exists regarding the negative outcomes of
these “sicker” patients.2
In this issue of the Journal of the American Heart
Association, Mark Navarro and colleagues3 completed a
thorough study from a different angle. We know the interven-
tionalists’ concerns are justified acutely as these CKD patients
have a higher level of inpatient complications,4 but these
authors chose to look at the patients 1 year from their event to
determine if a relationship existed between CKD and the
patients’ health status. In the current climate of patient-
centered care and outcomes, the study is very timely.
The investigators chose to use the Seattle Angina Ques-
tionnaire and Short Form-12 to collect data in a prospective
manner.3 The Seattle Angina Questionnaire assesses 5
domains of coronary artery disease health status. The quality
of life and angina frequency were used in the analysis. The
Short Form-12 is a 12-item survey of physical and mental
functioning. These score differences are related to the age-
specific mean score, with higher scores indicating better
health status. The cohort was 3617 patients with 16% of
these having CKD. In summary, the investigators looked at
angina frequency, quality of life, and overall functional status
in CKD and non-CKD patients 1 year from their coronary
event.3
Briefly, the investigators used the Translational Research
Investigating Underlying disparities in acute Myocardial
infarction Patients’ Health status registry5 and had the patients
complete the surveys at 1, 6, and 12 months. The analysis was
completed by using patients with an initial glomerular filtration
rate assessment, a baseline health status assessment, and ≥1
follow-up assessment. The highest glomerular filtration rate
was used to define CKD, which would bring one to the
possibility of the acute event contributing to a high glomerular
filtration rate, not truly meeting a criterion for CKD, but this
should not negate the outcomes.
The results are somewhat contradictory to what has been
reported previously. In the American Heart Journal article “The
prognostic importance of worsening renal function during an
acute myocardial infarction on long-term mortality” by Amin
and colleagues,6 worsening renal function was found to be
independently associated with an adverse long-term progno-
sis. These patients were followed for 4 years and they
followed patients with worsening of renal failure during the
acute event. Worsening of renal failure was found to be
independently associated with a higher risk of death.
In the study by Navarro, CKD does not seem to impact the
ultimate quality of life 1 year removed from the myocardial
infarction. Specifically, angina was not more frequent in the
CKD patients, mental functioning was similar regardless of
whether CKD existed, and the difference in physical function-
ing was not statistically significant.3
In the studied cohort, there is some positive data regarding
CKD patients 1 year removed from their myocardial infarc-
tion. The study is important clinically because these patients
should not be denied such proven interventions as cardiac
rehabilitation, cardiac support groups, and dietary counseling.
The CKD patient now should not be considered “too sick” to
benefit from these critical interventions. The authors are to be
applauded for changing, we hope, how the patient with CKD is
approached post myocardial infarction!
Now for the bad news. Why would this patient cohort have
lower discharge medication rates of aspirin, statin medica-
tions, and angiotensin-converting enzyme inhibitors? Previous
studies have shown the underuse of guideline-directed
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therapy in the CKD patient7,8; sadly, this was confirmed. The
concern of the elevated creatinine being caused by the acute
event comes into play again. Physicians may be hesitant to
start the angiotensin-converting enzyme inhibitor if they
perceive the renal injury is acute. The high-dose statin is
recommended for secondary prevention with no caveat
regarding CKD. In a meta-analysis by Nikolic,9 a conclusion
was proposed that statins may actually be protective to the
renal function in CKD patients not receiving dialysis, but the
benefit seemed to depend on duration of treatment. Finally,
the lack of use of aspirin is truly a bewilderment. Platelet
dysfunction in the uremic patient is a well-known clinical
syndrome but should not be a contributor to the lack of
aspirin use in a post–myocardial infarction patient. Many of
these patients should actually be taking dual antiplatelet
therapy with no contraindications in the CKD patients.10 To all
who read this, medical students, residents, fellows, and
attending physicians, the message is clear. Follow the
guidelines!1
In summary, the study’s authors should be commended for
looking at the entire picture of the CKD patient with acute
myocardial infarction and the clinical status 1 year post
myocardial infarction. These patients did as well as their non-
CKD counterparts from an angina and quality of life stand-
point. The outcomes of the study are significant in how these
patients are perceived and, we hope, treated. These data
reinforce the need to follow guideline-directed therapy in
these patients. The burning question remains: Why the
difference in aspirin, statin, and angiotensin-converting
enzyme inhibitor use in the CKD patient post myocardial
infarction? The lack of use of these therapies did not make
sense before this study and certainly even less so now.
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